Aptevo Therapeutics Inc (NASDAQ:APVO) – Investment analysts at Piper Jaffray Companies boosted their Q2 2019 earnings per share (EPS) estimates for Aptevo Therapeutics in a note issued to investors on Monday, April 15th. Piper Jaffray Companies analyst E. Tenthoff now forecasts that the biotechnology company will earn ($0.28) per share for the quarter, up from their previous forecast of ($0.29). Piper Jaffray Companies currently has a “Overweight” rating and a $4.50 target price on the stock. Piper Jaffray Companies also issued estimates for Aptevo Therapeutics’ FY2019 earnings at ($1.22) EPS, Q1 2020 earnings at ($0.26) EPS and FY2020 earnings at ($1.11) EPS.
Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research report on Thursday, March 14th. ValuEngine cut shares of Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Five investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $7.88.
Aptevo Therapeutics stock opened at $0.82 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.66 and a current ratio of 2.76. Aptevo Therapeutics has a 12-month low of $0.78 and a 12-month high of $6.35. The stock has a market cap of $35.42 million, a price-to-earnings ratio of -0.34 and a beta of 2.88.
Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Monday, March 18th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.09). Aptevo Therapeutics had a negative return on equity of 108.06% and a negative net margin of 232.68%.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Clifford Swan Investment Counsel LLC acquired a new stake in shares of Aptevo Therapeutics in the fourth quarter worth approximately $35,000. Deutsche Bank AG boosted its position in shares of Aptevo Therapeutics by 251.7% in the fourth quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock worth $419,000 after acquiring an additional 236,300 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of Aptevo Therapeutics by 4.8% in the fourth quarter. Acadian Asset Management LLC now owns 462,824 shares of the biotechnology company’s stock worth $587,000 after acquiring an additional 21,059 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Aptevo Therapeutics by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,442,049 shares of the biotechnology company’s stock worth $1,831,000 after acquiring an additional 16,482 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Aptevo Therapeutics by 11.1% in the third quarter. Renaissance Technologies LLC now owns 1,277,100 shares of the biotechnology company’s stock worth $6,488,000 after acquiring an additional 127,700 shares during the last quarter. 17.08% of the stock is currently owned by institutional investors and hedge funds.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Further Reading: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.